u/pavel_halvorsen

Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.

phase 3 data will change most of what gets said here

Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

Personal importation provisions exist, are narrow, and carry conditions.

hamza_serrano is right that the two countries are separate systems and the answers diverge.

Right, and the habits from the losing phase are the part that has to outlive the dose.

Personal importation provisions exist, are narrow, and carry conditions. Any summary of them here should be checked against the current official wording rather than a forum post.

Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.

The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.

Disagree that the pace matters as much as you think. Durable is better than fast and nobody posts about durable.

Yes.

rasmus_mensah is right that the clothes tell you before the scale does.

the monotherapy numbers are modest and that is not the point

That is preclinical work and the thread is treating it as a human finding.

The national shortage database is a primary source with expected resolution dates attached. It is public, searchable, and consistently more accurate than reporting about it.

Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.

Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.

Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.

Is the goal you set at the start still the goal?

Someone posted US advice in an Australian thread and it took four replies to untangle it. Say your country.

Careful — interval stretching and dose reduction are different interventions and your post uses them interchangeably.

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

I would not treat one pharmacy’s quote as the national price. Variation between them is substantial.

That is a pharmacy-level stock issue rather than a national supply issue. They feel identical and are not.

ask the pharmacy to check the wholesaler rather than guessing

I would not treat one pharmacy’s quote as the national price. Variation between them is substantial.

Not convinced. Two weeks of stable weight is not evidence of anything yet.

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

I would not treat a two-kilo range as a regain. Weight varies day to day in everybody.

Gently disagree with the framing — that is not a plateau, that is a month. They are different things.

the Medsafe position in New Zealand is its own thing entirely

Do you have a written baseline from before you started changing anything?

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

phase 3 data will change most of what gets said here

Wrote down where I was before changing anything. That single page made the following six months interpretable.

There is very little published guidance on stopping specifically, which is exactly why board consensus here should carry less weight than usual and a clinician conversation should carry more.

Not convinced. That is the New Zealand position and the thread is asking about Australia.

The national shortage database is a primary source with expected resolution dates attached.

Adding the quickest step — ask the pharmacist to check the wholesaler.